Slide 1: Orion Interim Report January–March 2023
Orion Interim Report January–March 2023 27 April 2023
Slide 2: Disclaimer
Disclaimer This presentation contains forward-looking statements which involve risks and uncertainty factors. These statements are not based on historical facts but relate to the Company’s future activities and performance. They include statements about future strategies and anticipated benefits of
Slide 3: Nubeqa (darolutamide) is Orion's top selling product
Nubeqa®(darolutamide) is Orion’s top selling product • Nubeqa® Orion’s top-selling product in Q1’2023 • New clinical phase III trial ARASTEP • Approvals for additional indication (mHSPC) in Japan, European Union and China 3 27 April 2023 © Orion Corporation
Slide 4: Year started in line with our expectations
Year started in line with our expectations Cash flow from • Net sales Net sales operating activities • Main positives: Nubeqa® and Animal Health per share • Main negatives: entacapone, Russia, dexmedetomidine and Simdax MEUR EUR • Factors explaining the decline in operating profit 277.9 0.03 • Fixed
Slide 5: Net sales bridge Q1'2022 to Q1'2023
Net sales bridge Q1’2022 to Q1’2023 1 Nubeqa® (product sales & royalty) 5 Other products and services (ex Animal Health and Fermion) 2 Simdax® & dexmedetomidine for human use 6 Exchange rates 3 Entacapone products 7 Animal Health & Fermion 4 Russia 5 27 April 2023 © Orion Corporation The figures in
Slide 6: Operating profit bridge Q1'2022 to Q1'2023
Operating profit bridge Q1’2022 to Q1’2023 ~EUR 10 million due to cost increase and changes in product mix ~EUR 17 million due to price decreases, of which significant part is explained by the fact that Orion supplied Nubeqa® to Bayer with lower price than in the comparative period 1 Product & servi
Slide 7: Business reviews
Business reviews 160 Sales split 140 -1% 120 7% 15% 100 10% 80 MEUR 21% 60 40 48% 20 0 Innovative Medicines Innovative Branded Generics & Animal Fermion Other* Branded Products -20 Medicines Products Consumer Health Generics & Consumer Health Health Animal Health Fermion 1-3/2022 1-3/2023 Other* 7 2
Slide 8: TOP 10 products in Q1 2023
TOP 10 products in Q1 2023 EUR vs. Product or product portfolio million 1−3/2022 1. Nubeqa® 38.2 +93.0% 2. Easyhaler® product portfolio 32.2 +3.3% 3. Entacapone products* 21.5 -37.1% 4. Simdax® 8.1 -34.6% 5. Dexdomitor®, Domitor®, Domosedan®, Antisedan® 8.0 +41.8% 6. Trexan® (rheumatoid arthritis, c
Slide 9: Innovative Medicines EUR 41.8 million (+89.0%)
Innovative Medicines EUR 41.8 million (+89.0%) • Nubeqa® sales EUR 38.2 million (+93.0%) Nubeqa® sales booked by Orion* 45 40 35 30 25 MEUR 20 15 10 5 0 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 2019 2020 2021 2022 2023 Product sales to Bayer Royalty *Orion’s sales to Bayer for commercial u
Slide 10: Branded Products EUR 59.5 million (-18.8%)
Branded Products EUR 59.5 million (-18.8%) 40 • Easyhaler® product portfolio Sales split 35 34.1 continued on a growth track 31.2 32.2 1% • The decline in entacapone 30 8% products mostly due to timing of 25 21.5 partner deliveries MEUR 20 • The decline in Divina® series 15 explained by contraction
Slide 11: Generics and Consumer Health EUR 133.7 million (-7.9%)
Generics and Consumer Health EUR 133.7 million (-7.9%) 120 • Generic competition pressing 109.7 Sales split by geographic the prices and sales of Simdax® 101.1 areas and dexmedetomidine products 100 for human use 80 • Contraction of business in Russia 21% also explaining the net sales MEUR 60 declin
Slide 12: Animal Health and Fermion
Animal Health and Fermion • Animal Health growth due to Animal Health Fermion acquisition of animal health 30 25 26.9 company VMD (Inovet) in June 25 20.2 2022 20 18.1 8.0 • Sedatives remain the largest 20 product group in Animal Health 15 • The decline in Fermion’s MEUR 15 13.2 reported external ne
Slide 13: Key clinical development pipeline
Key clinical development pipeline Project/compound Indication PHASE I PHASE II PHASE III REGISTRATION ARASENS / darolutamide 1 Prostate cancer (mHSPC) ARANOTE / darolutamide 1 Prostate cancer (mHSPC) ARASTEP / darolutamide 1 Prostate cancer (BCR) ODM-208 2 Prostate cancer (mCRPC) ODM-105 / tasipimid
Slide 14: Sustainability report 2022 is now published
Sustainability report 2022 is now published in Orion.fi – these are Orion’s sustainability highlights from 2022 Patient safety Active work for a Care for well-being Ethics at the core as a top priority better environment professionals of our business We were able to meet the We increased the focus o
Slide 15: Outlook for 2023
Outlook for 2023 Net sales Orion estimates that net sales in 2023 will be slightly higher than in 2022 without the EUR 228 million impact from ODM-208 upfront payment (net sales in 2022 without the impact of the ODM-208 upfront payment were EUR 1,113 million). Operating profit Operating profit is es
Slide 16: Basis for the outlook – key contributors
Basis for the outlook – key contributors Net sales Operating profit Nubeqa® Generic Nubeqa® Operating costs Animal Health competition COGS** Milestones* Milestones* Russia Simdax® and other declining Easyhaler® Pricing products pressure * Excluding ODM-208 upfront payment * Excluding ODM-208 upfront
Slide 17: Upcoming events
Upcoming events Capital Markets Day 25/5/2023 Half-Year Financial Report 17/7/2023 Interim Report 1-9/2023 26/10/2023